Two large pharma deals have been announced in the past 24 hours, both involving acquisition of companies with rare disease assets.
The first is Celgene’s $9 bn acquisition of the 90% of Juno Therapeutics it doesn’t already own. Juno is the pioneer of CAR T therapies (oncology immunotherapies) and has multiple R &D stage and marketed cancer therapeutic assets with orphan designation.
In the other M & A deal, Sanofi has stepped up with $11.6 bn to acquire Bioverativ, a company spun off from Biogen last year. Bioverativ specialises in drugs in the rare disease area of haemophilia.
https://www.forbes.com/sites/johann...uno-therapeutics-a-risky-9b-bet/#4d40eb5917c7
https://www.bloomberg.com/news/arti...ear-11-5-billion-deal-for-bioverativ-wsj-says
http://fortune.com/2018/01/22/why-sanofy-is-bying-bioverativ/
- Forums
- ASX - By Stock
- 2017...2018?
Two large pharma deals have been announced in the past 24 hours,...
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B |
Open | High | Low | Value | Volume |
$13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3816 | $13.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.78 | 2834 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3816 | 13.730 |
3 | 3430 | 13.720 |
1 | 1582 | 13.710 |
1 | 1807 | 13.690 |
1 | 1807 | 13.670 |
Price($) | Vol. | No. |
---|---|---|
13.780 | 2834 | 1 |
13.840 | 1623 | 2 |
13.870 | 1807 | 1 |
13.890 | 1807 | 1 |
13.910 | 1807 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online